Become a Member

Hodge’s pitch: “The first machine in the world that can detect this deadly virus on site is being rushed to market. “

What's this machine that Early Advantage teases can send a little stock from $1 to $20?

By Travis Johnson, Stock Gumshoe, March 13, 2020

This is the latest teaser pitch that a lot of folks have been asking about — and rightly so, I expect, because it’s designed to be extremely topical and get you revved up immediately. Here’s the intro to the ad that I’ve seen in some Angel Publishing newsletters:

“We’re now in crisis mode over coronavirus — which is why you need to invest in a new machine that can identify the virus on-site… in just 60 minutes! It’s a total game changer for the fight against this deadly outbreak. Dozens of government agencies are putting in orders now… and the $1 shares of the company behind this machine could soar to $20 or more in the weeks ahead…”

And the headline of the actual ad is more of the same:

“URGENT UPDATE:

“US Authorities are Desperate to Keep Coronavirus from Spreading Across America…

“The first machine in the world that can detect this deadly virus on site is being rushed to market.

“If you act now, this machine’s $1 stock shares could easily soar to $20 or more in the weeks ahead.”

Which is what everyone wants, right? We all want much more availability of testing for coronavirus, to help more reasonably quarantine those who are actually infected, and it would be delightful to find a stock that might climb while everything else is collapsing. It’s a pretty easy sell.

So what, then, is the ad about? Well, first of all, it is an ad — so the main point is to urge you to sign up for Nick Hodge’s Early Advantage, currently being sold at $1,299 a year (though unlike some of the higher-cost letters, he does at least offer a refund “guarantee” period).

And the order form pretty well sums up the pitch:

“This Machine Can Save a Million Lives in 60 Minutes

“It detects viruses: coronavirus, SARS, swine flu…
“It detects bacteria: E. coli, listeria, staph…
“Threat of outbreaks could send this machine’s $1 shares to $20 or more in the weeks ahead!….

“This machine is so effective it will soon be used for airports, military bases, public facilities, universities, school cafeterias, and restaurants across the country.

“It was designed by a top-level Pentagon scientist with a long list of winners under his belt.

“This machine is about to take over the disease detection market and make early investors wealthy…

“There’s a $40+ Billion Market Up for Grabs — You Have Just Days to Get in on the Ground Floor”

So what’s the stock? Well, they even go so far as to include a photo of the little machine he’s talking about, so we can confirm that this is, again, a pitch for a stock that Nick Hodge was touting a few years ago — and one line in there is pretty critical:

“Threat of outbreaks could send this machine’s $1 shares to $20 or more in the weeks ahead!”

So no, it’s not sales, or revenue, or the use of the machine that will boost the company’s business… it’s threat of outbreaks that Hodge thinks could boost the stock by 20X.

Which I read as, “there might be a mania over this stock” — and, of course, if you sell that idea to a few million of your closest friends, you might be able to create a self-fulfilling prophecy (sorry, perhaps that’s a wee bit too cynical).

But yes, this is still Lexagene (LXG.V, LXXGF), which Hodge has been teasing as a pathogen-finder since the summer of 2017. It was roughly a 50-cent stock then, and it’s roughly a 50-cent stock now, so if this is going to turn into something dramatic, well, at least you haven’t missed it yet.

Here’s how the company describes itself:

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


“LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.”

The initial push in 2017 was for this to be used as a food safety testing device, letting producers test for things like e. coli in water or food products before it reaches thousands of salads. At the time, the first prototype had been built and was being shown off at a couple trade shows, which was the spur that Hodge thought would lead to huge orders and a surge in the share price (the stock did go up for a few months, whether from that advance or from Hodge’s attention we’ll never really know).

So what’s the story now? Well, LexaGene has indeed sent out a few press releases about the suitability of its machines for coronavirus testing… though they’ve also been pretty nimble over the years in issuing timely press releases for hot-button topics, from antibiotic resistance to cannabis testing, all of which has generally overplayed the suitability of the machine for these hot sectors and underplayed the fact that they don’t actually have a machine to sell yet.

LexaGene did introduce their prototype testing machine back in the summer of 2017, then a LX2 beta prototype aimed at the veterinary market about a year later, which was successful in pilot testing last year at identifying pathogens causing urinary tract infections. The then beta-tested their device at a regular lab to do human urinary tract assays, and last Fall found pretty good correlation with traditional testing methods.

So last fall, they again started talking about “commercialization,” following another financing in October. Here’s what they said:

“Dr. Jack Regan, LexaGene’s CEO and Founder states, ‘This financing puts the Company in a very strong position to advance our commercial development goals. We’ve gone from being a company with a vision and R&D focus to carrying out beta testing, and now we’re ramping up for our commercial build.’

“Management is using these funds to expand the development team in the areas of mechanical, electrical, and software engineering to speed the Company’s ability to evaluate and finalize different components for the commercial design of the LX2™ Genetic Analyzer. These components will enhance performance, lessen time-to-result, improve manufacturability and serviceability, as well as lower costs for the final commercial build.”

And as soon as coronavirus hit the headlines in January they reported that “we can detect that” and then, just this week, issued a “corporate update” and announced that they’ll be working to accelerate their “emergency use authorization” with the FDA to use their LX Analyzer machine, which they’re seeking to partner with someone soon to beta test in the field for coronavirus testing. Here’s the CEO this week:

“The rapid spread of the novel disease COVID-19, with infections reported in more than 90 countries and 37 U.S. states, highlights the failure of existing diagnostics to contain a novel pathogen successfully. To contribute to the solution for this outbreak and make us better prepared for the next outbreak, LexaGene is now aggressively pursuing the clinical diagnostics market. We also have the personnel in place to remain on track to penetrate veterinary diagnostics, food safety and other markets that require open-access testing.”

As of now, though they’re really still talking about designing the machine — they contracted with an industrial design firm to “accelerate commercialization efforts” and are tinkering with components and layout of the machine for cost and efficiency. And though this sounds wildly optimistic from an outside perspective, they now say that

“We’re doing each step of development properly and we are on track to deliver a next-generation pathogen detection system in Q3 of this year”

I don’t know what “deliver” means, maybe that just means a third prototype will be available in six months, but there seems almost no chance that Lexagene is going to play any role in coronavirus testing for this current outbreak. I would assume that if we’re talking about mass testing, which still eludes us in the US, we’re probably going to see antibody tests that can be done quickly in a doctor’s office using blood, like they did in China, not genetic assays (even more rapid ones like Lexagene’s). I’d say it’s a near certainty that there won’t be LX Analyzers commercially available for coronavirus testing in doctor’s office this year, though there is clearly some appeal in the idea and I wish them the best.

And frankly, over the long run I’d caution that even though this testing machine sounds impressive and it would be great to know if you have an antibiotic-resistant urinary tract infection in an hour instead of day or two, the rollout of any system like this will be largely driven by economics — I had a doctor 15 years ago who had her own on-site blood testing lab, mostly because she dealt with a lot of AIDs and Hepatitis patients, and my insurance would never cover her in-house testing because they had a better deal with the local mega-lab. That insurance infrastructure will be tough to crack, which might be part of the reason why they shifted to a veterinary product after the first prototype was complete.

For now, LexaGene is still what it was 2-1/2 years ago: A company trying to develop and then sell a commercial testing machine that can use different assays to genetically identify pathogens that for food safety and testing customers, doctor’s offices, and veterinarians. They haven’t finalized a design yet, but their technology looks like it works.

Unfortunately, it’s a public company and didn’t get a big bolus of venture funding at the start, probably because they’re going up against so many massive testing equipment companies (notice those names who are talking about tests and testing equipment now, and getting government contracts? I’m seeing Roche mentioned a lot, with their $250+ billion market cap, along with Thermo Fisher Scientific at $112 billion, down to the “small” players like Qiagen at about $9 billion, which makes a little $50 million company like LexaGene seem even more inconsequential).

So that means they have to raise money by press release — generate some attention, try to get the stock price up, then sell more shares to keep the project moving forward for a few more months. They’ve been burning through about $10 million a year in cash, which presumably will accelerate if they actually try to get the first device through prototype stage and into final development and regulatory approval, so the $5 million they raised most recently (in October) probably won’t last them much longer… they were down to $3.75 million at the end of November and I haven’t seen any announcement of the next fundraising yet, so unless they snuck an equity sale in there in the past couple months that I didn’t notice, I’d expect to probably see that within the next month or two.

The shares did climb in January and February as the coronavirus (and perhaps Hodge’s promotions) brought them some more attention, getting the shares up to 90 cents or so (Canadian), but then when everyone sold everything this past week they sold LexaGene, too, and it’s back to C$0.57 as I type. That’s roughly where it was before they announced their first prototype, though they’ve sold a lot of stock in the interim so the market cap has almost doubled since then (from C$25 million to just under C$50 million).

Here’s what I wrote back in the summer of 2017 about this one, and my opinion hasn’t really changed in the interim:

“Seems interesting, but I have no idea of what demand will be or what the competing products and testing regimes are (there are many, this particular device is NOT mandated by anyone and hasn’t even been built yet), so I don’t see any reason to rush into this early stage penny stock. High risk, possibly high reward, completely uncertain financial future — I’d really have to ‘buy in’ to management’s vision to be excited at this early stage.”

Your opinion might vary, of course, that’s what makes a market — just don’t buy this stock because you think the machine will be used for coronavirus testing this year… and if you get excited about it and the stock does surge on coronavirus news or progress, I’d suggest keeping an eye on it so you can sell that excitement before it comes back to reality again. LexaGene and the LX Analyzer might end up being great, but they’re not ready for prime time — and my guess is that the company would probably be much better off if they were making their prototype progress with dedicated venture capital funding and a partnership with a big company instead of trying to raise $5 million at a time to keep their project moving forward.

If you think I’m being too conservative, or have other thoughts on LexaGene, I’d be delighted to hear them — just use the happy little comment box below.

Irregulars Quick Take

Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)
guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

35 Comments
Inline Feedbacks
View all comments
obviously
obviously
March 13, 2020 3:00 pm

Roche news 10x faster testing

👍 21650
tanglesome
tanglesome
March 13, 2020 3:13 pm

My father emailed me saying he nibbled on Lab Corp. (LH) and Quest Diagnostics (DGX) as they’re testing and he thinks (big if) they’ll be the first manufacturers of a vaccine. https://www.adweek.com/brand-marketing/labcorp-quest-diagnostics-say-coronavirus-testing-is-available-but-you-have-to-go-to-your-doctor/

Add a Topic
5849
Add a Topic
1623
👍 126
👍 21650
vivian lewis
March 13, 2020 3:43 pm

as a shareholder in Roche of Switzerland and Thermo Fisher of the US, I am a long-term follower of genetic array diagnostic stocks. this is a field for large well-capitalized firms not mini-startups. I would love to find a tiny firm with great possibilities but this idea is not it

nobody
Guest
nobody
March 13, 2020 4:58 pm
Reply to  vivian lewis

“I would love to find a tiny firm with great possibilities but this idea is not it”
vivian, I can’t promise ‘this is it’ but you might be interested enough to look into it. There’s a write-up in the latest issue of the UK mag Investors Chronicle about BATM (XLON.BVC), a small but diverse company. Apparently their kit for diagnosing Covid-19 has been tested by labs and hospitals, though I saw nothing like an FDA approval or equivalent from other countries. Currently they’re working on large scale manufacture at a low enough cost, but I don’t know if that’s low enough for hospitals or in-the-field. It conforms to CDC recommendations. The text has been posted on the UK investment site advfn, on 12/03/2020 00:04 (that’s UK dating, 12th March). I suppose the posting breaks copyright, but it happens often enough that that’s why I looked there, after reading the piece in the mag. I’m long BVC (and from before Covid-19).

Add a Topic
6183
Add a Topic
3022
Dexter Dawson
Guest
Dexter Dawson
March 14, 2020 4:18 pm
Reply to  vivian lewis

Hi Vivian, can you elaborate why you think this is not the idea. Curious to know what a veteran like yourself thinks. Thanks!

Cleveland
March 13, 2020 4:05 pm

Thank you Travis for your presentation. I am a shareholder so I am biased.

I have analyzed the capital in depth and will add light later. It is not near as dire as you present.

There are multiple applications of the LX analyzer that must be evaluated. Several have been Beta Tested. Veterinary diagnostics is the one I am keen on.

To me the Coronavirus application is irrelevant. It is a complete sideshow and does not deserve much print. IMHO they should JV with a major diagnostic company the Coronavirus app.

The Nick Hodge piece came out before the company’s 3/11/20 press release.

Here are the important parts of the press release:

“Over the last several months, LexaGene has made significant enhancements to the LX Analyzer, resulting in advanced performance while reducing manufacturing costs for improved margins of the commercial unit. The Company has begun manufacturing some of the more complicated components of the instrument, such as its optical module, and made several improvements to the analyzer’s design, including:

Design work for improved manufacturing and serviceability

30% reduction in size for an upgraded optical module

40% reduction in manufacturing costs for improved unit pricing15-fold improvement in sensitivity due to a new sample prep cartridge (from initial data)

A new fluidic configuration that reduces number of pumps and valves by half Progress towards developing software to improve system usability

Furthermore, the Company has recently contracted an internationally renowned industrial design firm, Ximedica, to accelerate its commercialization efforts.  In addition, the Company is in the final stages of hiring key positions in sales, product marketing, quality, regulatory affairs, engineering, and application support.

The Company expects to announce some of these hires in the near future. LexaGene President and Co-founder Daryl Rebeck concludes, “LexaGene’s progress has been tremendous. We’re doing each step of development properly and we are on track to deliver a next-generation pathogen detection system in Q3 of this year.”

My comment: Since Lexagene is following the razor blade model so the 40% reduction in cost is huge.

How many units must LexaGene sell to achieve positive cash flow? What is the projected profitability of each cartridge sold? I have all this.

How many potential profit centers are there?

The key to understanding Lexagene is to know Dr. Jack Regan the CEO.

Again thank you for your coverage.

Add a Topic
10907
Add a Topic
9799
👍 6080
Tacman
Member
Tacman
March 13, 2020 5:35 pm
Reply to  Cleveland

Strange, that nowhere is the mention of any prioritize protective design patents or even patents pending on development. Doesn’t sound like anything that other more established Companies couldn’t be doing and more likely have it already done had they found it to be worthwhile.

niizajim
March 13, 2020 10:14 pm
Reply to  Tacman

Just curious, but why in the world would you assume that any company would pursue something like this without patents? Silliness!

👍 976
Lorenzodeleon
Guest
Lorenzodeleon
March 25, 2020 10:48 pm
Reply to  niizajim

NiizaJim, are you a graduate of CAJ? LL ’69

bludolphint
September 15, 2020 6:05 pm
Reply to  Tacman

I believe they have 4 or more patents that they received in the early days at Livermore, and a couple patents pending. Numbers could be off but I do know they have them.

👍 188
AC/DC
AC/DC
March 13, 2020 10:18 pm
Reply to  Cleveland

Thanks for the detailed comment Cleveland. Key is indeed knowing Dr. Regan.

👍 2034
Cleveland
March 14, 2020 1:01 pm
Reply to  Cleveland

There are many layers and potential profit centers for Lexagene. The one that I am most excited about is Lexagene Veterinary Diagnostics.

Instead of sample results in one to three days how about One hour.

See the Beta Test video below. Note there are no FDA or other regulatory approvals required.

There are 90 million dogs in USA and  95 million cats. There are some 5.4 million urine sediment tests per year in USA.  73,000 veterinarians.

I wrote an entire paper on how the 92 million Millennials and their pet ownership are changing the landscape for pet ownership (67% of Millennials own pets) To Millennials their pets are Family i.e. my millennial daughter bought her pet dog an Advent Calendar. True.  

“LexaGene opens up a whole new opportunity in the area of Veterinary Diagnostics with LX Analyzer, a patented automated microfluidic technology, is designed to be operated at the site of sample collection and can produce accurate test results in approximately 1 hour, which is a drastic improvement over the 1-3 day typical turn around time for an offsite reference laboratory to process samples. Lay people can run the test, no special training needed.Imagine if instead of waiting days for culture and sensitivity test results, you could get results in just 1 hour.

Dr. Sam Stewart DVM, DACVECC, Commercialization Scientist Fellow at Ethos Veterinary Health reports:

“LexaGene’s analyzer is really going to be a game changer.  Our team’s enthusiasm for this technology has been so overwhelming, we’ve asked LexaGene to allow some of our other hospitals to beta test the technology.” 

Samuel Stewart, goes on to say further: “Emergency veterinarians are frustrated that there are no easy-to-use instruments to rapidly and accurately detect infectious diseases inside the hospital. This is a problem, as there are many conditions and diseases that may or may not be caused by an infectious organism,” said Dr. Jack Regan, CEO and Founder of LexaGene. “For example, the symptom of incontinence in a dog could be due to a urinary tract infection (UTI), bladder cancer, kidney or bladder stones, diabetes, Cushing’s disease, prostate gland disease, and relative estrogen withdrawal.”

“This will completely change what we do and how quickly we do it.” Rebecca Davies, DVM DACVECC Mass Vet Referral Hospital Ethos Veterinary Health Network of 24 hospitals nationwide; Beta testing conducted at Mass VET “I believe that this could be a revolutionary advancement in the Emergency and Critical Care field in both human and veterinary medicine.

”Video testimonials from the veterinary team can be viewed in the following video. The following is a Video of the Beta Prototype TEST at Massachusetts Veterinary Referral Hospital (4 min):

VIDEO

https://lexagene.com/beta-testimonial-video/ 

LexaGene  is initially planning to enter the  Veterinary Diagnostics market in in animal hospitals. Their goal is to run genetic analysis in an hour and to provide reliable answers while the patient is still in clinic.

LexaGene’s automated LX Analyzer is designed for in-hospital use and takes < 1 min to start.  The Analyzer performs a series of genetic tests to screen for multiple pathogens and antibiotic resistance factors at once, providing the data to boost confidence in initial diagnoses and any prescribed therapies. LexaGene’s technology meets critical needs of underserved markets·         Fast turnaround time (~1 hour)·          Great sensitivity and specificity·          Open-access (customizable)·          Anyone can operate –load in seconds·          Low cost per sample tested  Advantages Automated, rapid testing using our LX Analyzer has significant advantages over traditional methods of testing like culture and sensitivity testing which is accurate but slow, or immuno-assay tests that are fast and less accurate. Improve your patient care and clinic workflow. ·         Easy-to-use Load a raw sample and a cartridge onto the analyzer, enter sample ID, and press ‘Go’.No sample prep or skilled technician are required.·         Fast results – onsiteTest onsite, process 2 samples at a time. Rapid results reducing “time-to-result” from days to about one hour.·         Sensitivity and specificityProcess a significant sample volume for better, more accurate detection.  The analyzer uses real-time PCR for ultra-sensitive detection, and its high level of multiplexing allows for improved specificity.·         Multiplex Syndromic Testing Screen up to 27 genetic targets per test for pathogen identification and the presence of common drug resistance genes.·         Open-access Run our validated assays or your own assays for customized testing.  Ideal for detecting novel or newly emergent pathogens.·        Compact Powerful functionality contained in a small footprint for placement in clinics.·         Connected Electronically records data for interfacing with patient records and for easy retrieval of historical data."

Add a Topic
3022
Add a Topic
1508
Add a Topic
3397
👍 6080
bludolphint
September 15, 2020 6:12 pm
Reply to  Cleveland

Excellent comments. I just spent a half hour adding my thoughts about the co, and all I had to do was to agree and add DITTO! Great points. I am a shareholder and thus very biased.

👍 188
bludolphint
September 15, 2020 6:01 pm
Reply to  Cleveland

Well said, I am also a fan and shareholder.

Add a Topic
LXG
👍 188
Joe Rivkin
Member
Joe Rivkin
March 13, 2020 4:31 pm

Well written analysis with a good perspective on reality!

brianmdixon
Member
brianmdixon
March 13, 2020 4:33 pm

Stay healthy yourself, Travis. We need your sane and considered views as panic hits everywhere,, and disinformation is spreading faster than the coronavirus – some of it from on high.

Add a Topic
9799
👍 11
lc_fort
Irregular
lc_fort
March 13, 2020 4:59 pm

What about the Sona Nanoech devices (https://sonanano.com/) ?
Any hopes in the short-term ?

👍 9
Dexter Dawson
Guest
Dexter Dawson
March 13, 2020 6:57 pm

You mentioned that stock was up in Jan and Feb due to Corona virus first hitting then. You forgot to mention that the stock shot up almost two fold in December, BEFORE, the corona virus scare. I believe Lexagene will eventually get their commercial unit out there and start generating revenues. In the meantime, there is a ton of trading / headline / news value, esp now that it’s back down to .40 cents USD. Don’t see much downside from here, but any type of news…. ready to go to market, some sort of FDA approval for emergency use, anything, will take this stock back up to .70 cents. It’s very volatile, and I think it’s a great entry point here. Betting man – stock will be higher than were it is now, as we approach 3Q launch date. Stock has done it many times before. Just pull up the chart. There’s a good story here and they will keep churning out interesting press releases, and with commercial launch coming, I highly doubt stock will be trading at these levels.

Add a Topic
6483
Add a Topic
4656
Add a Topic
4656
👍 21650
Dexter Dawson
Guest
Dexter Dawson
March 13, 2020 7:42 pm

I agree with you, they missed the coronavirus opportunity. But I think there is value beyond coronavirus. All the markets that are potential targets, like veterinary, etc. Lex is basically a start-up. It takes a long time to get things to market. Not uncommon to see delays as companies try to find product market fit. I think it’s very important for the company to get a commercial unit out there and move away from ‘tinkering’ and alpha, beta, pre-commerical, etc. Just get a working commercial out there. FDA doen’t want to deal with a company that doesn’t have a commercal unit out there. So I think if they execute well and actually get commercial units out in the field and generating revenues in 3Q, stock will be at a different level. Of course, if they don’t execute, we can see more downside. But my bet is on Jack and his team to launch the unit and generate revs. Once they have working commercial units out there, they can focus on the next pandemic, which everyone knows is going to come again…

Add a Topic
9799
Add a Topic
5953
Johnboyy2g
Johnboyy2g
March 13, 2020 8:44 pm

LXXGF is not really about Covid 19. This company is not about press releases. They could bring rapid testing for this outbreak with FDA approval. But as Cleveland tried to point out, this company has a viable machine. The profit is in the kits, not the machine. It is extremely rapid, Roche’s machine takes four times longer. Lexagene is more sensitive and is designed for field use, onsite, now. Not shipping samples to a remote lab that will take several days to run the tests. In addition, Lexagene is an open source machine. In other words, if you want to run a test on Roche’s machine, Riche must have already designed the test kit for you to test for the target you are searching for. Lexagene is open source, you can design your own test kit to look for your target. Lexagene should NOT be considered as a quick flip. This is a company that will be a great play in a year or less, with the following fields they can sell off. The veterinary sector, the food testing sector, the cannabis sector tests, and lastly the human testing sector. And, there is a huge subsection of the human testing sector, how many units and test kits will be bought not just be Doctor’s offices and hospitals but by the military? Every Navy ship with a hospital bed, front line MASH units, mobile infantry units, the WHO and CDC, advance field units.

Add a Topic
5794
Add a Topic
3022
bludolphint
September 15, 2020 6:15 pm
Reply to  Johnboyy2g

Excellent points, thank you.

👍 188
Vaughn
Vaughn
March 13, 2020 7:00 pm

Well done Travis! Yet again you throw the ice water challenge at those who might’ve been gullible to have bought into this ‘sizzle’ without the steak! Truly, you are the gumshoe when it comes to the deep digging, like what their burn rate is, and where they actually are on the market!
Courtesy of that and more, I’ll be taking a pass on this stock. And a big tip of the hat to you!

Add a Topic
2493
Add a Topic
540
freddy-potless
freddy-potless
March 13, 2020 8:19 pm

Beware Nick Hodge. Snake oil salesman supreme.

Add a Topic
1437
Add a Topic
359
👍 24
socr
socr
March 21, 2020 5:55 am
Reply to  freddy-potless

He’s a pump and dump schemer

big tuna
March 14, 2020 11:23 am

I held lexagene for sometime and sold at a significant loss as could never seem to get going. It has a good back story but for some reason sputters out. I also think that in the big picture testing and diagnosing is futile effort since it is contagious before symptomatic. The moneymaker is going to be treatment.and cure. Vaccines and testing are spilt milk under the bridge.

👍 299
t27fp3a
Irregular
t27fp3a
March 17, 2020 12:40 pm

The stock has been dropping lately due to the large amount of warrants that came due on March 13 ( It seems like a lot of buyers decided to exercise their rights at 0.65 cents, so it watered down the price . The carnage of the TSX, and the whole stock market has also made a big impact on the stock . If one has done their own due diligence I think this is a good time to continue to keep averaging down ( playing with what one is willing to lose ). There are two great investors that I really like ; Warren Buffet and Peter Lynch . Their views pertain to this stock, for me. Warren Buffet said to look for the stock with experience management and the stock that has cutting edge for time and cost savings . Peter Lynch said to look for the need in the place that we work ; a lot of us come from the healthcare field or we are associated with family members etc that are. He also said to look at the time we live in . We are not just dealing with this pandemic , we are dealing with different generations with different needs. An example is that a lot of us have pets today. A beloved dog is part of the family and they fulfill different needs . Many children want a dog and parents give in because they love their kids , which often becomes parent’s responsibilty. Some seniors have a dog not just to break the loneliness but it helps them to walk outside daily. Many millennials see their dogs as their fur-babies. I have even heard their parents refer to the dogs as their ‘ grand dogs. ” The point I am trying to say is that when it comes to this member of the family people will spare no expense to see them happy and healthy again. The faster the diagnosis and treatment the better it is for concern pet owners.If you go to the LXG website you can see the broad fields that the LX2 machine covers plus you can see the global reach on this unique, fast and accessible technology for the present global market. The LX2 is a 4th generation technology from LLNL.
I know that about 75 percent of penny stocks will become junk . I also know that there is no guarantee on any stock but I continue to stick with LXG due to the fact it came out of LLNL LLNL’s mission is to strengthen USA security via conventional warfare, cybersecurity, natural and bio engineered threats. Last time I look LLNL also maintain America’s nuclear weapons.About 6000 people work for LLNL . Budget is about $40 billion. This LLNL initial technology is still presently part of the Biowatch program , which is run by Homeland Security ( covering about 80 % of America ) . If you go to Penn Station it is the size of a microwave oven ; suction in the air and testing it for dangerous pathogens. Since 9/11 this technology has been in use at major events in the USA. Past technologies out of LLNL such as most of our computer parts, GPS , Human Genome Mapping , , Chromosone Paintings etc have had huge markets and world wide implications..As per the FLC article it took Dr Jack Regan about 7 years before he could own the technology, that he came up with for LLNL. A partnership was then formed through a Mutual Nondiclosure Agreement in February 2015 with LLNL via LLNS. Remember that the goal of LLNS is the commercialization of technology developed by LLNL for THE BENEFIT OF THE USA ECONOMY . If you read further you will notice that LXG has an exclusive right to sell its product out of LLNL. Remember the reach and connection of LLNL world wide.. American’s research and development is a big part of its economy and source of pride to the USA.. Dr Regan and LLNL have several patents on the technology. Any pirating of LLNL technology is seen as striking at the Heart of America, especially in the Trump Era of .” Make America Great Again.
LLNL has already spent $20 million on the first prototype after 9/11. Dr Jack Regan was the lead scientist on this technology to prevent bio terrorist attack of anthrax , that was been sent through the mail…, that is why he was able to have access to it, but only after much finagling with LLNL…
Once again please look at back ground LXg board members and managers . Remember that Tom Slezak just retired from LLNL last year . He worked there for about 40 years . He was part ogf Biowarch and the Human Genome Project. He also was the leader of SARS when it first struck in America. He served on the CDC plus he served on NAS about 3 times. NAS members usually are up to date on the latest scientific and they deliver their findings to congress. Monahar Furtado served in 2011 under Kathleen Sebellius, Former US secretary of Health and Human Services for USA Disaster Planning. He was part of Cepheid Board when it sold for $52 a share ( was initially a penny stock in its early day before it started on the NASDAQ at about $6/ share..( PCR came out of LLNL a while back ). M Furtado owns a business call Biology for the Global Good. The goal is global reach one day ( see Bill and Melinda Gates foundation and their goal also ).
You can also see that Lexagene has already started bulding their reach for when they enter the market. The first Chief veterinarian for DHS and chief Scientist for the office of Health Affairs job was to advise Secretary of Homeland Security on strategies and emergency response plans for food and agriculture. He would have set the mold and others have built on it. I am sure he still have some reach. Dr James Marsden also just retired from Chipotle, after he was brought in to change their plummettng stock after noravirus, ecoli outbreaks etc. Through ‘ best practice ‘ he left the stocks 50 % higher when he left . He has also testified in front of congress on food safety. There is also Shawn Stevens ,who has the only law firm that handles the big business of food recall. As the founder of The Food Industry Counsel he will have the ears of those large food distribution, processors, growers etc.
I have followed LXG in its ALPHA and BETA days. In the beginning I was lucky enough o talk with the CEO and have him answer questions for 31 minutes. I was also trying to get a sense of his integrity . He delivered on my requirements. I also know that LLNL vet all its scientists and other top workers . They even go back into their childhood . Honesty and integrity is a big requirement due to they are trusted with information that can have major impact on the safety of the USA.
My only concern now is I saw an interview where the CEO appeared to be frustrated with CDC and their slowness to act ( Remember that LXG initially set their goal to work on the vet and food industries before they enter the human market because it was easier to access. Human market would mean going through the FDA with all its hurdles.The caronavirus has now cause them to put the effort in the human machine now. FDA stated that they will give EUA to the right diagnostic tool. LXG has already shown that its BETA is 100 % on par with the CDC machine. In a few years I have seen a computer in my time go from table top fit in a phone in the palm of my hand ; I think it is just hop skip and a jump to see a reference lab in the size of machine that is the size of a coffee percolator. BOTH TECHNOLOGIES DERIVE FROM LLNL.place .While you are at it please read National Action Plan On Antibiotic resistance. Read up on USA goal to drive down broad spectrum antibiotic use and the implication for Medicaid 2020 to 2025.

Add a Topic
3229
Add a Topic
3949
👍 10
👍 21650
russell
Guest
russell
April 15, 2020 11:49 am

Join the discussion…I cant even find that on the stock ticker is its value zero

👍 21650
Bosko
Bosko
April 13, 2020 11:35 am

I think Biocept Inc looks like a little fire cracker that could turn into a rocket. The ticket symbol is BIOC. Any thoughts on this one anyone?

Add a Topic
4149
bludolphint
September 15, 2020 5:49 pm

That is a fair assessment Travis. Since March they have now the machine that will be put into production and they have a new name for the machine and they will be in production in Oct.. I think. They have talked to the FDA and know what is required for the EUA and they are quickly working to meet that goal. A couple of things that I thought were important. The co. uses the name MiQlab and it was being developed for food safety at distribution points-it still is. It is already rolled out to vets; the point being it still is targeting these markets and will in the future. The fact is that it just takes an adjustment to the machine and it is capable of detecting the COVID virus. When that is over the next virus that comes in the future will also be detected by the machine. In conjunction with the FDA discussions they have placed the machines in a Mass. hospital to test the results compared t0 other testing methods and results over the last month or so are very high close to 97% or higher accurate. They have sales staff hired and a manufacturing facility lined up which brings me to the razor blade model. The cartridges that are used for the test materials are disposed after every use and are ordered from the co. Another point that caught my attention is that even though listed on the Toronto exchange it is an American co. and it is its intention to list on an American ex. very soon. That was mentioned early on and was one thing that attracted me to it. So the markets they started to target, (vet, food safety etc.) are not going anywhere. They are still in the sights. Say McDonalds or the co that sells them lettuce for example would gladly test that lettuce in an hour or less to avoid one bad publicity event like food poisoning. Or the multistate salmonella pathogen linked to onions just recently. Or a hospital having several units to quickly diagnose whatever virus is ravaging the country. In 1 hour. What would a patient rather have right now, 1 hr. or 1 or 2days to know if they have to self-isolate? And they don’t have to hire new staff to run the machine, just an hours training is needed for say, the receptionist to be able to run the machine. And every test uses a disposable plastic container. It is clear that I am biased and I do own shares that I add to every time it takes a dip. Their intention is to be selling in Sept. or October. I think they will at least be selling and making units this year and of course if the EUA comes through that will start the ball rolling. But the thing is that while it waits for the FDA for that it doesn’t change the other markets it is selling to. I just like the flexibility; that it can be changed to whatever pathogen that comes along. Please don’t take my word for it. If you want to look at their website and do your own research. There are a number of catalysts that are very near term that can give a good bounce to the stock. The big ones are the FDA EUA and the imminent listing on a main US Exchange. I could go on but I won’t. It is worth a look.

Add a Topic
5794
👍 188
OSUfball
Irregular
November 17, 2020 5:54 pm

Lexagene is finally no longer just an R&D outfit, but an actual company with a real product. They announced this week the first sale of the MiQLab to a large multinational pharma company. The pharma will be using the MiQLab to test for contaminants in its bioreactors. This is an open access use case that no one talked about before. The open access market dwarfs the vet, covid, and food testing market. There are so many use cases for this device. The company is going to shortly announce sales in the veterinary market. The big share price mover will be when FDA EUA for Covid19 testing is obtained, which is estimated to be around January 2021. I think the share price is a bargain at the current levels, less than $1 USD.

Add a Topic
3022
👍 321

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info  
32
0
Would love your thoughts, please comment.x
()
x